DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hallermann-Streiff syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHallermann-Streiff syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hallermann-streiff syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
gap junction protein alpha 1 (GJA1) — GJA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7Z1T · 2.26 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Hallermann-Streiff syndrome is rare, with approximately 150 case reports in the world literature as of 1999. The syndrome consists of proportionate nanism; hypotrichosis; atrophy and extreme thinness of the skin, particularly over the facial area; an unusual bird-like face with mandibular hypoplasia; a prominent thin, pointed nose; congenital cataracts; and severe dental abnormalities. It appears to be a sporadic mutation, and the inheritance pattern is unknown. In a 1999 series of 15 patients, five had produced normal chromosome studies, none had similarly affected siblings, and four had normal, unaffected children. Most patients underwent multiple reconstructive procedures and did relatively well. Eleven of the 15 patients encountered significant intermittent respiratory difficulty manifested as early feeding difficulty, recurrent upper respiratory tract infection, sleep apnea, and respiratory arrest. Three patients required tracheostomy because of respiratory difficulty, and one child died of postoperative respiratory compromise.
Two cases reported in 2015 identified ophthalmic signs including microphthalmos, cataract, and fundus abnormalities, with visual functions determined by these factors. A 2015 case report of a 9-year-old female child presented with abnormal facial features, dental problems, and associated cardiac problems. The 1999 report notes that clinical management must focus on life-threatening and developmental issues early on, with early surgical correction of cataracts to preserve vision and early attention to airway issues. Reconstructive procedures including rhinoplasty, facial augmentation, and mandibular surgery have been successful and can be performed after the adolescent growth period.
No drug treatment is mentioned in any of these abstracts. The evidence consists entirely of case series and case reports, with no controlled trials, no molecular target identified, and no pharmacological intervention tested. What is still missing is any understanding of the genetic cause, any animal model, any drug screening effort, any funding for systematic natural history studies, and any trial design that could test a repurposed drug in a condition this rare.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Craniofacial Surgery · 1999 · 52 citations
Hallermann-Streiff Syndrome
AbstractHallermann-Streiff syndrome is rare, with approximately 150 case reports in the world literature. The syndrome consists of proportionate nanism; hypotrichosis; atrophy and extreme thinness of the skin, particularly over the facial area; an unusual "bird-like" face with mandibular hypoplasia; a prominent thin, pointed nose; congenital cataracts; and severe dental abnormalities. This appears to be a sporadic mutation, and the inheritance pattern is unknown. Clinical management must focus on the more life-threatening and developmental issues early on, and aesthetic deformities can be addressed after the adolescent growth period is complete. Surgical correction of cataracts should be undertaken early in life to preserve vision. Airway issues need to be addressed early. Other reconstructive procedures, including rhinoplasty, facial augmentation, and mandibular surgery, have been successful and can be performed later in life. We report on our clinical findings in 15 patients with this condition, our attempts at reconstruction, and complications we have encountered in treating this patient population. Five of our patients had produced normal chromosome studies, and none have had similarly affected siblings. Four have had normal, unaffected children. Most of our patients have undergone multiple reconstructive procedures and have done relatively well. Eleven of our patients, however, have encountered significant intermittent respiratory difficulty manifested as early feeding difficulty, recurrent upper respiratory tract infection, sleep apnea, and respiratory arrest. Three patients required tracheostomy because of respiratory difficulty, and one child died of postoperative respiratory compromise. The management of these complicated and difficult patients is discussed.
Two Cases of Hallermann-Streiff Syndrome with Retinal Abnormalities
AbstractHallermann-Streiff syndrome is a rare congenital disorder \nthat is characterized by malformations of the craniofacial \nregion with ocular abnormalities. Some ophthalmic signs can \nbe observed in early age and some in adulthood. The visual \nfunctions are determined by a lot of factors including \nmicrophthalmos, cataract and fundus abnormalities. We report \ntwo cases of Hallermann-Streiff syndrome identified in our \ndepartment in the last decade.
Hallermann Streiff Syndrome-The Oral Manifestations in a Child
AbstractHallermann-Streiff syndrome (HSS) is a rare genetic disorder that is primarily characterized by distinctive malformations of the skull and facial region, sparse hair, eye abnormalities, dental defects, atrophic skin changes and a proportionate short stature. Here we discuss a case of 9 years-old female child who presented with abnormal facial features, dental problems and associated cardiac problems.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
